Ассоциация полиморфизма +405C > G (rs2010963) с подверженностью к метаболическому синдрому: кардио-метаболические факторы риска и концентрация матриксной металлопротеиназы-3

Обложка

Цитировать

Полный текст

Открытый доступ Открытый доступ
Доступ закрыт Доступ предоставлен
Доступ закрыт Только для подписчиков

Аннотация

В настоящем исследовании мы изучали роль нуклеотидной замены +405 в гене VEGF в патогенезе метаболического синдрома и анализировали ее связь с несколькими биохимичесимим факторами риска. Было генотипировано 150 пациентов с метаболическим синдромом и 50 здоровых людей с помощью PCR-RFLP. Биохимические показатели в сыворотке оценивали с помощью ELISA. Среди пациентов с метаболическим синдромом преобладал генотип CG. У них же было повышено содержание триглицеридов, снижено содержание липопротеинов высокой плотности и аланинаминотрансферазы. Показано, что изучаемая замена может быть предиктором метаболических нарушений при метаболическом синдроме. Подтверждение этого вывода требует увеличения выборки.

Об авторах

Лейла Никниаз

Исследовательский центр Управления Медицинскими услугами; Тебризский университет медицинских наук

Email: nikniaz@yahoo.com
Scopus Author ID: 25031589500
Иран, Тебриз, ул. Аттар Нейшабури

Махди Аббасализад-Фарханги

Тебризский университет медицинских наук

Автор, ответственный за переписку.
Email: abbasalizad_m@yahoo.com
Иран, Тебриз, ул. Аттар Нейшабури

Список литературы

  1. Reaven GM. Role of insulin resistance in human disease. Diabetes. 1988;37(12):1595–1607. doi: 10.2337/diab.37.12.1595
  2. Heshmat R, Hemati Z, Qorbani M, et al. Metabolic syndrome and associated factors in Iranian children and adolescents: the CASPIAN-V study. J Cardiovasc Thorac Res. 2018;10(4):214–220. doi: 10.15171/jcvtr.2018.37
  3. Zhang X, Lerman LO. The metabolic syndrome and chronic kidney disease. Transl Res. 2017;183:14–25. doi: 10.1016/j.trsl.2016.12.004
  4. Kim D, Touros A, Kim WR. Nonalcoholic fatty liver disease and metabolic syndrome. Clinics in liver disease. 2018;22(1):133–140. doi: 10.1016/j.cld.2017.08.010
  5. Ghanei Gheshlagh R, Parizad N, Sayehmiri K. The relationship between depression and metabolic syndrome: systematic review and meta-analysis study. Iran Red Crescent Med J. 2016;18: e26523-e. doi: 10.5812/ircmj.26523
  6. Mottillo S, Filion KB, Genest J, et al. The metabolic syndrome and cardiovascular risk: A systematic review and meta-analysis. J Am Coll Cardiol. 2010;56(14):1113–1132. doi: 10.1016/j.jacc.2010.05.034
  7. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA. 2002;287(3):356–359. doi: 10.1001/jama.287.3.356
  8. Zabetian A, Hadaegh F, Azizi F. Prevalence of metabolic syndrome in Iranian adult population, concordance between the IDF with the ATP III and the WHO definitions. Diabetes Res Clin Pract. 2007;77(2) 251–257. doi: 10.1016/j.diabres.2006.12.001
  9. Miyazawa-Hoshimoto S, Takahashi K, Bujo H, et al. Elevated serum vascular endothelial growth factor is associated with visceral fat accumulation in human obese subjects. Diabetologia. 2003;46:1483–1488. doi: 10.1007/s00125-003-1221-6
  10. Watson CJ, Webb NJ, Bottomley MJ, Brenchley PE. Identification of polymorphisms within the vascular endothelial growth factor (VEGF) gene: correlation with variation in VEGF protein production. Cytokine. 2000;12(8):1232–1235. doi: 10.1006/cyto.2000.0692
  11. Kim YR, Hohong S. Association between the polymorphisms of the vascular endothelial growth factor gene and metabolic syndrome. Biomed Rep. 2015;3(3):319–326. doi: 10.3892/br.2015.423
  12. Moradzadegan A, Vaisi-Raygani A, Nikzamir A, Rahimi Z. Angiotensin converting enzyme insertion/deletion (I/D)(rs4646994) and Vegf polymorphism (+405G/C; rs2010963) in type II diabetic patients: Association with the risk of coronary artery disease. J Renin Angiotensin Aldosterone Syst. 2015;16:672–680. doi: 10.1177/1470320313497819
  13. Ray D, Mishra M, Ralph S, et al. Association of the VEGF gene with proliferative diabetic retinopathy but not proteinuria in diabetes. Diabetes. 2004;53(3):861–864. doi: 10.2337/diabetes.53.3.861
  14. Zafar MI, Mills K, Ye X, et al. Association between the expression of vascular endothelial growth factors and metabolic syndrome or its components: a systematic review and meta-analysis. Diabetology & metabolic syndrome. 2018;10:62–72. doi: 10.1186/s13098-018-0363-0
  15. Siervo M, Ruggiero D, Sorice R, et al. Body mass index is directly associated with biomarkers of angiogenesis and inflammation in children and adolescents. Nutrition. 2012;28(3):262–266. doi: 10.1016/j.nut.2011.06.007
  16. Kimura K, Hashiguchi T, Deguchi T, et al. Serum VEGF – as a prognostic factor of atherosclerosis. Atherosclerosis. 2007;194(1):182–188. doi: 10.1016/j.atherosclerosis.2006.07.025
  17. Szaflik JP, Wysocki T, Kowalski M, et al. An association between vascular endothelial growth factor gene promoter polymorphisms and diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol. 2008;246:39–43. doi: 10.1007/s00417-007-0674-6
  18. Petrovič D, Verhovec R, Petrovič MG, et al. Association of vascular endothelial growth factor gene polymorphism with myocardial infarction in patients with type 2 diabetes. Cardiology. 2007;107(4):291–295. doi: 10.1159/000099064
  19. Hagberg CE, Mehlem A, Falkevall A, et al. Targeting VEGF-B as a novel treatment for insulin resistance and type 2 diabetes. Nature. 2012;490:426–430. doi: 10.1038/nature11464
  20. Kanaki T, Bujo H, Mori S, et al. Functional analysis of aortic endothelial cells expressing mutant PDGF receptors with respect to expression of matrix metalloproteinase-3. Biochem Biophys Res Commun. 2002;294(2):231–237. doi: 10.1016/S0006-291X(02)00468-0
  21. Silvestre JS, Mallat Z, Tamarat R, et al. Regulation of matrix metalloproteinase activity in ischemic tissue by interleukin-10: role in ischemia-induced angiogenesis. Circ Res. 2001;89(3):259–264. doi: 10.1161/hh1501.094269
  22. Chang C, Werb Z. The many faces of metalloproteases: cell growth, invasion, angiogenesis and metastasis. Trends Cell Biol. 2001;11(1): S37–S43. doi: 10.1016/S0962-8924(01)82222-4
  23. Murphy G, Nagase H. Localizing matrix metalloproteinase activities in the pericellular environment. FEBS J. 2011;278(1):2–15. doi: 10.1111/j.1742-4658.2010.07918.x
  24. Thorp E. Contrasting inflammation resolution during atherosclerosis and post myocardial infarction at the level of monocyte/macrophage phagocytic clearance. Front Immunol. 2012;3:39–49. doi: 10.3389/fimmu.2012.00039
  25. Lijnen HR, Maquoi E, Demeulemeester D, et al. Modulation of fibrinolytic and gelatinolytic activity during adipose tissue development in a mouse model of nutritionally induced obesity. Thromb Haemost. 2002;88(2):345–353. doi: 10.1055/s-0037-1613208
  26. Gummesson A, Hägg D, Olson FJ, et al. Adipose tissue is not an important source for matrix metalloproteinase-9 in the circulation. Scand J Clin Lab Invest. 2009;69:636–642. doi: 10.3109/00365510902912747
  27. Miksztowicz V, Muzzio ML, Royer M, et al. Increased plasma activity of metalloproteinase 2 in women with metabolic syndrome. Metabolism. 2008;57(11):1493–1496. doi: 10.1016/j.metabol.2008.06.001
  28. Cicero AFG, Derosa G, Manca M, et al. Vascular remodeling and prothrombotic markers in subjects affected by familial combined hyperlipidemia and/or metabolic syndrome in primary prevention for cardiovascular disease. Endothelium. 2007;14(4–5):193–198. doi: 10.1080/10623320701606731
  29. Barylski M, Kowalczyk E, Banach M, et al. Plasma total antioxidant activity in comparison with plasma NO and VEGF levels in patients with metabolic syndrome. Angiology. 2009;60(1): 87–92. doi: 10.1177/0003319708327165
  30. Farzi A, Hagh MF. Association between Vascular Endothelial Growth Factor (VEGF) +405 C/G polymorphism and hypertension in North West of Iran. Int Res J App Bas Sci. 2014;8:122–125.
  31. Buraczynska M, Ksiazek P, Baranowicz-Gaszczyk I, Jozwiak L. Association of the VEGF gene polymorphism with diabetic retinopathy in type 2 diabetes patients. Nephrol Dial Transplant. 2007;22(3):827–832. doi: 10.1093/ndt/gfl641
  32. Jahangiry L, Shojaeizadeh D, Najafi M, et al. ‘Red Ruby’: an interactive web-based intervention for lifestyle modification on metabolic syndrome: a study protocol for a randomized controlled trial. BMC Public Health. 2014;14:748–754. doi: 10.1186/1471-2458-14-748
  33. Jahangiry L, Shojaeizadeh D, Najafi M, et al. ‘Red Ruby’: an interactive web-based intervention for lifestyle modification on metabolic syndrome: a study protocol for a randomized controlled trial. BMC public health. 2014;14(1):748. doi: 10.1186/1471-2458-14-748
  34. Farhangi MA, Jahangiry L, Mirinazhad MM, et al. A web-based interactive lifestyle modification program improves lipid profile and serum adiponectin concentrations in patients with metabolic syndrome: the “Red Ruby” study. Int J Diab Dev C. 2015;37:21–30. doi: 10.1007/s13410-015-0395-z
  35. Mirinazhad MM, Farhangi MA, Jahangiri L, Yaghoubi A. Serum adiponectin concentrations in relation to lipid proffle, anthropometric variables and insulin resistance in patients with metabolic syndrome. Malay J Nutr. 2014;20:283–289.
  36. Douvaras P, Antonatos DG, Kekou K, et al. Association of VEGF gene polymorphisms with the development of heart failure in patients after myocardial infarction. Cardiology. 2009;114(1):11–18. doi: 10.1159/000210189
  37. Miller SA, Dykes DD, Polesky HFRN. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988;16(3):1215–1219. doi: 10.1093/nar/16.3.1215
  38. Awata T, Inoue K, Kurihara S, et al. A common polymorphism in the 5'-untranslated region of the VEGF gene is associated with diabetic retinopathy in type 2 diabetes. Diabetes. 2002;51(5):1635–1639. doi: 10.2337/diabetes.51.5.1635
  39. Kowalski J, Sliwczyńska-Rodziewicz D, Kowalczyk E, et al. Plasma nitric oxide and vascular endothelial growth factor levels in patients with metabolic syndrome and co-existing vascular complications. Pol Merkur Lekarski. 2011;30:249–252.
  40. Altinkaya SO, Ugur M, Ceylaner G, et al. Vascular endothelial growth factor +405 C/G polymorphism is highly associated with an increased risk of endometriosis in Turkish women. Arch Gynecol Obstet. 2011;283:267–272. doi: 10.1007/s00404-009-1344-1
  41. Kim OkJ, Hong SH, Oh SH, et al. Association between VEGF polymorphisms and homocysteine levels in patients with ischemic stroke and silent brain infarction. Stroke. 2011;42(9):2393–2402. doi: 10.1161/STROKEAHA.110.607739
  42. Huez I, Bornes S, Bresson D, et al. New vascular endothelial growth factor isoform generated by internal ribosome entry site-driven CUG translation initiation. Mol Endocrinol. 2001;15(12):2197–2210. doi: 10.1210/mend.15.12.0738
  43. Vander Meer P, de Boer RA, White HL, et al. The VEGF +405 CC promoter polymorphism is associated with an impaired prognosis in patients with chronic heart failure: a MERIT-HF substudy. J Card Fail. 2005;11(4):279–284. doi: 10.1016/j.cardfail.2004.11.006

Дополнительные файлы

Доп. файлы
Действие
1. JATS XML
Скачать
2. Рисунок. Результаты ПЦР для полиморфизма гена +405 VEGF. GC: гетерозиготный (469 + 195 + 274 п.н.), GG: мутантный гомозиготный (274 + 195 п.н.), CC: дикий гомозиготный (469 п.н.). L: лестница ДНК 50 п.н.

Скачать (65KB)
Метаданные

© ООО "Эко-Вектор", 2021


 


Данный сайт использует cookie-файлы

Продолжая использовать наш сайт, вы даете согласие на обработку файлов cookie, которые обеспечивают правильную работу сайта.

О куки-файлах